
Investors Eye Lead Plaintiff Role in ADMA Biologics Class Action
Investors who purchased ADMA Biologics stock between August 9, 2024, and March 25, 2026, face a critical August 10 deadline to seek appointment as lead plaintiff in a federal class action lawsuit. The litigation, filed in New Jersey, accuses the biopharmaceutical company of systemic financial misrepresentation.


























